Welcome to our dedicated page for BioVie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on BioVie stock.
BioVie Inc. (OTC Pink: BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative drug therapies for chronic and debilitating conditions. The company's primary areas of research include chronic liver diseases, neurological disorders, and certain cancers.
BioVie's lead drug candidate, BIV201, targets ascites, a severe complication associated with advanced liver cirrhosis caused by hepatitis, non-alcoholic steatohepatitis (NASH), or alcoholism. Ascites affects approximately 100,000 Americans and has a high mortality rate of around 40% within two years of diagnosis. BIV201, based on the drug terlipressin, is currently entering a Phase 2 clinical trial in the US. Terlipressin is already approved in about 40 countries for treating liver cirrhosis complications, highlighting the potential of BIV201 to address a significant unmet medical need in the US. Notably, the FDA has not yet approved any drug specifically for ascites, and BIV201 has obtained orphan drug status.
Besides its liver disease program, BioVie is also advancing its NE3107 candidate, aimed at treating neurological and neuro-degenerative disorders. The company is conducting a Phase 3 randomized, double-blind, placebo-controlled study to evaluate NE3107 in patients with mild to moderate Alzheimer's disease. Additionally, NE3107 has shown promise in improving both motor and non-motor symptoms in Parkinson's disease, with significant improvements observed in patient trials.
BioVie has secured strategic investments from prominent investors, including Aspire Capital, Cuong Do (Global Strategy Lead for Samsung), and Hari Kumar (Founder of Adheron Therapeutics). These partnerships underscore the confidence in BioVie's innovative drug development pipeline.
Recent studies and presentations have highlighted the potential of NE3107 in addressing Alzheimer's and Parkinson's diseases. For instance, NE3107-treated patients exhibited improvements in cognitive and functional measures, biological age deceleration, and metabolic inflammation-driven systems dysregulation. These findings suggest that NE3107 could significantly impact core symptoms of these conditions by modulating inflammation and enhancing insulin sensitivity in the brain.
BioVie remains committed to advancing its clinical programs and delivering novel therapies to improve the lives of patients suffering from these challenging conditions.
BioVie (Nasdaq:BIVI) and bioAffinity Technologies (Nasdaq:BIAF) will appear on the RedChip Small Stocks, Big Money show on Bloomberg TV on July 6 at 7 p.m. ET. Cuong Do, President and CEO of BioVie, will discuss their late-stage clinical programs for neurodegeneration and liver disease. BioVie's lead asset, bezisterim, has shown promise in treating Parkinson's and Alzheimer's diseases by reducing inflammation, improving motor control, cognition, and brain imaging. BioVie plans to launch a Phase 2b trial for Parkinson's in Fall 2024 and a Phase 3 trial for Alzheimer's in mid-2025.
Maria Zannes, President and CEO of bioAffinity Technologies, will provide a corporate update, highlighting CyPath Lung's success in early-stage lung cancer detection. The test has demonstrated high sensitivity and specificity, with commercialization already underway. The lung cancer screening market is projected to hit $5.7 billion by 2030. bioAffinity's AI-enhanced flow cytometry platform is also being developed for COPD and asthma diagnosis. The company holds extensive patents and is backed by strong insider ownership (39%).
BioVie presented the upcoming SUNRISE-PD Phase 2 trial design at ATMRD 2024, evaluating bezisterim (NE3107) on motor and non-motor symptoms in early Parkinson's disease patients. The trial will involve 60 participants, randomized to receive either bezisterim or placebo for 12 weeks. Key objectives include assessing motor symptom improvements, non-motor symptoms, and overall PD symptoms. In parallel, they presented Phase 2a data showing bezisterim's potential as an adjunctive therapy to carbidopa/levodopa, with significant improvements in motor functions and non-motor symptoms like sleep and restlessness. These findings support further evaluation in a larger trial. If successful, participants may join a future long-term safety study.
BioVie and Mobilicom will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing June 22 at 7 p.m. ET. BioVie's CEO, Cuong Do, discusses the company's late-stage clinical programs targeting neurodegeneration and liver disease, highlighting their lead asset, bezisterim, which has shown promising results in clinical trials for Parkinson's and Alzheimer's diseases. Key milestones include a Phase 2b trial for Parkinson's in Fall 2024 and a Phase 3 trial for Alzheimer's in mid-2025.
Mobilicom's CEO, Oren Elkayam, will talk about their investment opportunities. Mobilicom's products, like SkyHopper Datalinks and the ICE Cybersecurity Suite, have led to significant market penetration, with 50 customers in 18 countries. The company achieved 43% revenue growth and a 59% gross margin in 2023, ending the year with $8.4 million in cash, indicating a solid financial position to execute their strategic plans.
BioVie announced two poster presentations at the ATMRD Congress in Washington, D.C., from June 21-25, 2024. The presentations will focus on the Phase 2 trial protocol for bezisterim (NE3107) in early Parkinson’s patients and its impact on motor and non-motor symptoms, specifically for those not yet treated with carbidopa/levodopa. The first poster will be displayed on June 22 from 5-5:30 p.m. EDT, outlining the study protocol. Another poster will be shown the same day from 4:20-4:50 p.m. EDT, featuring data on bezisterim’s effects when used alongside carbidopa/levodopa.
BioVie (NASDAQ: BIVI), a clinical-stage company focused on neurological, neurodegenerative, and liver diseases, will host a live investor webinar on June 26, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Cuong Do, discussing the company's clinical pipeline, including bezisterim (formerly NE3107). Bezisterim has shown promising results in reducing inflammation, insulin resistance, and improving symptoms in Parkinson's and Alzheimer's diseases. Strategic priorities include a Phase 2b trial for Parkinson's in Fall 2024, a Phase 3 trial for Alzheimer's in mid-2025, and ongoing partnering discussions.
BioVie announced the formation of an Advisory Board to guide the Phase 2b trial of bezisterim for long COVID, funded by a $499,200 award from the U.S. Department of Defense. The board includes experts from UCSF and Northwestern Feinberg School of Medicine, and industry veterans.
The trial aims to evaluate bezisterim, an anti-inflammatory and insulin-sensitizer, for reducing neurocognitive symptoms in long COVID patients. The trial, involving 200 patients, will assess safety and efficacy over three months.
The Department of Defense may provide an additional $12.6 million upon successful completion of the planning phase and meeting specific milestones.
BioVie announced promising results from a Phase 2a trial of their drug bezisterim for Parkinson's disease. Data presented at the XXIX World Congress on Parkinson's Disease and Related Disorders showed that patients treated with bezisterim in combination with levodopa/carbidopa experienced significant improvements in both motor and non-motor symptoms compared to placebo. Notably, bezisterim-treated patients saw a -2.8 point improvement on the motor section of the MDS-UPDRS scale. For patients under 70, the improvement was -4.7 points. Additionally, bezisterim-treated patients showed significant gains in sleep/fatigue and leg restlessness symptoms. These findings suggest bezisterim's potential as an adjunct therapy, warranting further investigation in late-phase trials.
BioVie Inc. (NASDAQ: BIVI) secured up to $13.1 million from the U.S. Department of Defense for a Phase 2b clinical trial evaluating bezisterim (NE3107) in treating long COVID symptoms. Long COVID is a condition where symptoms persist post SARS-CoV-2 infection. The trial aims to assess the drug's effectiveness in reducing neurological symptoms associated with long COVID. Bezisterim, an anti-inflammatory and insulin-sensitizer capable of permeating the blood-brain barrier, targets inflammation, a key factor in long COVID. The trial is expected to begin in early 2025 and includes 200 patients.
FAQ
What does BioVie Inc. specialize in?
What is BIV201?
What is NE3107?
Why is BIV201 significant?
Who are some of BioVie's strategic investors?
What recent achievements has BioVie made?
What are the primary focus areas of BioVie's research?
How does NE3107 work?
What is the market potential for BIV201?
How can investors and media inquire about BioVie?
